French Pharma Stock News

Arkema (ENXTPA:AKE) just signed a strategic MoU with Chinese battery separator specialist Semcorp, targeting next generation separator technologies for electric vehicles, energy storage systems and consumer electronics, and supporting Semcorp’s global expansion. See our latest analysis for Arkema. The MoU lands at a tricky moment for Arkema, with the share price at €52.3 after a 1 week share price return of 3.56 percent but a much weaker year to date share price return of negative 26.96...

Vinci (ENXTPA:DG) just stepped up its share buyback program, snapping up nearly 387,000 shares, while traffic on its motorways and airports keeps grinding higher, despite a less favorable calendar this year. See our latest analysis for Vinci. Those steady motorway and airport gains help explain why the share price is holding up, with a strong year to date share price return of around 21 percent and a robust 1 year total shareholder return of roughly 26 percent suggesting momentum is still...

TotalEnergies and Google recently signed a 21-year Power Purchase Agreement for 1 TWh of certified renewable electricity from the planned Citra Energies 20 MW solar plant in Kedah, Malaysia, to support Google’s data center operations. This long-term deal highlights how hyperscale tech companies are increasingly locking in dedicated clean power projects, reinforcing TotalEnergies’ role as a large-scale partner in the energy transition. We’ll now explore how this long-duration Google PPA,...

C-Tech, a New Zealand–owned advanced composites manufacturer, recently selected Dassault Systèmes’ 3DEXPERIENCE platform on the cloud to modernize its end‑to‑end design, engineering and manufacturing workflows, improving simulation accuracy and collaboration. This adoption highlights how Dassault Systèmes is extending the reach of its cloud-based 3DEXPERIENCE offering into Asia-Pacific advanced manufacturing, underscoring growing appeal across specialized, high-performance industries. We’ll...

As European markets navigate a mixed landscape with slight declines in the STOXX Europe 600 Index and varying performances across major indices, investors are keenly watching for signals from the European Central Bank regarding potential rate hikes amid resilient economic conditions. In this environment, dividend stocks can offer a compelling opportunity for income-focused investors seeking stability and consistent returns, making them an attractive consideration as we explore some top picks...

SPIE (ENXTPA:SPIE) just deepened its relationship with Tesla through a multi year European framework agreement for battery energy storage projects, a strategic move that plugs SPIE directly into the grid scale transition story. See our latest analysis for SPIE. Those moves sit against a strong backdrop, with the share price up sharply this year on the back of the Tesla framework, energy transition acquisitions and an upcoming anti dilutive buyback, signalling building momentum and improving...

As an investor, mistakes are inevitable. But really bad investments should be rare. So consider, for a moment, the...

Société BIC (ENXTPA:BB) is shaking up its perimeter by shutting down Rocketbook and its Skin Creative tattoo brands while also cancelling nearly 760,000 treasury shares, a combination that directly reshapes both operations and capital structure. See our latest analysis for Société BIC. The latest moves come after a choppy year for Société BIC, with a 1 year to date share price return of minus 22.83 percent but a more resilient 5 year total shareholder return of 31.43 percent. This suggests...

Sodexo S.A. ( EPA:SW ) has announced that it will be increasing its dividend from last year's comparable payment on the...

As the European market experiences mixed movements with indices like Germany’s DAX and Italy’s FTSE MIB seeing gains while France's CAC 40 and the UK’s FTSE 100 face declines, investors are closely watching economic signals from central banks. In this environment, dividend stocks can offer a measure of stability and income, making them an attractive option for those seeking to navigate uncertain market conditions.

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

With a price-to-earnings (or "P/E") ratio of 20.8x Aubay Société Anonyme ( EPA:AUB ) may be sending bearish signals at...

Adocia SA ( EPA:ADOC ) shareholders won't be pleased to see that the share price has had a very rough month, dropping...

Key Insights Technip Energies' significant retail investors ownership suggests that the key decisions are influenced by...

There wouldn't be many who think STEF SA's ( EPA:STF ) price-to-earnings (or "P/E") ratio of 16.4x is worth a mention...

If you are wondering whether Engie is still good value after such a strong run, or if you are turning up late to the party, this breakdown will help you decide whether the current price still makes sense. Engie’s share price has barely moved over the last week (up 0.4%) and month (down 0.3%). However, those quiet short term moves sit on top of a 40.0% gain year to date and a 58.6% rise over the past year, with returns of 110.9% over 3 years and 158.8% over 5 years. Part of this strength...

Sanofi recently reported that its PERSEUS Phase 3 trial found the multiple sclerosis drug tolebrutinib failed to delay disability progression in primary progressive MS, leading the company to stop seeking approval for this indication while the FDA review for non‑relapsing secondary progressive MS is pushed beyond the previously expected December 2025 decision date. At the same time, Sanofi has expanded its presence in rare blood disorders in China with approvals for Qfitlia in hemophilia and...

Airbus (ENXTPA:AIR) has slid about 6% over the past month, even though the stock is still up roughly 20% year to date, a pattern that has many investors rechecking their assumptions. See our latest analysis for Airbus. That recent 6.6% one month share price pullback comes after a strong run driven by double digit revenue and earnings growth, and with a 24.5% one year total shareholder return, momentum looks more paused than broken at this point. If Airbus has you rethinking aerospace...

If you are wondering whether Pluxee is a beaten down opportunity or a value trap at its current price, this is a good place to unpack what the market might be missing. The stock has been choppy lately, up 1.8% over the last week but still down 4.5% over 30 days and roughly 29% lower year to date. This naturally raises questions about whether sentiment has swung too far. Recent coverage has focused on Pluxee's standalone positioning in employee benefits and engagement solutions following its...

Edenred recently announced a partnership with Daimler Truck to power the TruckCharge semi-public electric charging network across Europe, using its Spirii e-mobility software and extending Mercedes Benz electric trucks’ access to the UTA Edenred public charging network of roughly 420 truck-compatible stations in 23 countries. This move positions Edenred’s Spirii platform at the core of a large-scale heavy-vehicle charging ecosystem, reinforcing its role in the road transport energy...

Wondering whether STMicroelectronics is a bargain or a value trap at current levels? You are not alone, but we can walk through the numbers in a clear and practical way. After a choppy few years that left the stock down 34.3% over three years and 23.9% over five, the recent 8.4% rise over the last month suggests sentiment might be starting to shift, even though it is still down 7.3% year to date and 8.8% over the past year. Investors have been reacting to a mix of macro signals from the...

ABIVAX Société Anonyme (ENXTPA:ABVX) has just posted its Q3 2025 numbers, with revenue of about €2.0 million and a basic EPS of roughly -€2.10, while trailing 12 month figures sit at €6.8 million in revenue and EPS of around -€4.46. The company has seen revenue hover in a narrow band between about €0.97 million and €2.0 million over the last few quarters, while EPS has remained firmly negative throughout that stretch. This highlights a story driven more by pipeline progress than by near term...